💊
Galafold
migalastat
Fabry Disease
✅ Authorised
✅
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Galafold is indicated for long-term treatment of adults and adolescents aged 12 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation (see the tables in section 5.1).
⚠️ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/galafold